The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine

Alemnew F Dagnew, Nicola P Klein, Caroline Hervé, George Kalema, Emmanuel Di Paolo, James Peterson, Bruno Salaun, Anne Schuind, Alemnew F Dagnew, Nicola P Klein, Caroline Hervé, George Kalema, Emmanuel Di Paolo, James Peterson, Bruno Salaun, Anne Schuind

Abstract

Background: Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients.

Methods: Adults aged ≥65 years who were previously vaccinated with ZVL ≥5 years earlier (n = 215) were group-matched with ZVL-naive individuals (n = 215) and vaccinated with RZV. Glycoprotein E (gE)-specific humoral and cell-mediated immune responses and the correlation between them, polyfunctional gE-specific CD4 T-cell responses, safety, and confirmed HZ cases were assessed.

Results: Through 12 months after dose 2, anti-gE antibody concentrations, gE-specific CD4 T-cell frequencies, and activation marker profiles were similar between groups. Safety outcomes were also similar. No HZ episodes were confirmed.

Conclusions: RZV induced strong humoral and polyfunctional cell-mediated immune responses that persisted above prevaccination levels through 1 year after dose 2 in adults aged ≥65 years irrespective of previous ZVL vaccination. The RZV safety profile was not affected.

Clinical trials registration: NCT02581410.

Keywords: Herpes zoster; Adjuvanted recombinant zoster vaccine; Live-attenuated herpes zoster vaccine; Persistence of immune response; Polyfunctionality; Safety.

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Participant flow diagram. Abbreviations: ATP, according-to-protocol; HZ-NonVac, no previous vaccination with live-attenuated herpes zoster (HZ) vaccine before administration of adjuvanted recombinant zoster vaccine (RZV); HZ-PreVac, previous vaccination with live-attenuated HZ vaccine ≥5 years before administration of adjuvanted RZV; TVC, total vaccinated cohort; y, years.
Figure 2.
Figure 2.
Frequency of glycoprotein E (gE)–specific CD4 T cells expressing any combination of activation markers (according-to-protocol cohort for immunogenicity). A, Mean gE-specific CD4 T-cell frequencies. B, Relative mean gE-specific CD4 T-cell frequencies. C, Activation marker combinations (error bars represent interquartile ranges). Abbreviations: CD40L, CD40 ligand; HZ-NonVac, no previous vaccination with live-attenuated herpes zoster (HZ) vaccine before administration of adjuvanted recombinant zoster vaccine (RZV); HZ-PreVac, previous vaccination with live-attenuated HZ vaccine ≥5 years before administration of adjuvanted RZV; IFN-γ, interferon γ; IL-2, interleukin 2; mo, month(s); TNF-α, tumor necrosis factor α.
Figure 2.
Figure 2.
Frequency of glycoprotein E (gE)–specific CD4 T cells expressing any combination of activation markers (according-to-protocol cohort for immunogenicity). A, Mean gE-specific CD4 T-cell frequencies. B, Relative mean gE-specific CD4 T-cell frequencies. C, Activation marker combinations (error bars represent interquartile ranges). Abbreviations: CD40L, CD40 ligand; HZ-NonVac, no previous vaccination with live-attenuated herpes zoster (HZ) vaccine before administration of adjuvanted recombinant zoster vaccine (RZV); HZ-PreVac, previous vaccination with live-attenuated HZ vaccine ≥5 years before administration of adjuvanted RZV; IFN-γ, interferon γ; IL-2, interleukin 2; mo, month(s); TNF-α, tumor necrosis factor α.

References

    1. Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26:728–43.
    1. Cohen JI. VZV: molecular basis of persistence (latency and reactivation). In: Arvin A, Campadelli-Fiume G, Mocarski E, et al, eds. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge, United Kingdom: Cambridge University Press, 2007.
    1. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341–57.
    1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4:e004833.
    1. Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015; 15:502.
    1. Oxman MN, Levin MJ, Johnson GR, et al. . Shingles Prevention Study Group . A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271–84.
    1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:1–30; quiz CE2-4.
    1. Gabutti G, Valente N, Sulcaj N, Stefanati A. Evaluation of efficacy and effectiveness of live attenuated zoster vaccine. J Prev Med Hyg 2014; 55:130–6.
    1. Morrison VA, Johnson GR, Schmader KE, et al. . Shingles Prevention Study Group . Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60:900–9.
    1. Schmader KE, Oxman MN, Levin MJ, et al. . Shingles Prevention Study Group . Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55:1320–8.
    1. Tseng HF, Harpaz R, Luo Y, et al. . Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years. J Infect Dis 2016; 213:1872–5.
    1. Weinberg A, Popmihajlov Z, Schmader KE, et al. . Persistence of varicella-zoster virus cell-mediated immunity after the administration of a second dose of live herpes zoster vaccine. J Infect Dis 2019; 219:335–8.
    1. Lal H, Cunningham AL, Godeaux O, et al. . ZOE-50 Study Group . Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087–96.
    1. Cunningham AL, Lal H, Kovac M, et al. . ZOE-70 Study Group . Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375:1019–32.
    1. Cunningham AL, Heineman TC, Lal H, et al. . ZOE-50/70 Study Group . Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis 2018; 217:1750–60.
    1. Bastidas A, Catteau G, Volpe S, et al. . 2905. Long-term immunological persistence of the adjuvanted recombinant zoster vaccine: clinical data and mathematical modeling. Open Forum Infect Dis 2019; 6:S84–S5.
    1. Grupping K, Campora L, Douha M, et al. . Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis 2017; 216: 1343–51.
    1. Dooling KL, Guo A, Patel M, et al. . Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103–8.
    1. Sullivan NL, Reuter-Monslow MA, Sei J, et al. . Breadth and functionality of varicella-zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans. J Virol 2018; 92:e00269–18.
    1. Vesikari T, Hardt R, Rümke HC, et al. . Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother 2013; 9:858–64.
    1. Sei JJ, Cox KS, Dubey SA, et al. . Effector and central memory poly-functional CD4+ and CD8+ T Cells are Boosted upon ZOSTAVAX® vaccination. Front Immunol 2015; 6:553.
    1. Qi Q, Cavanagh MM, Le Saux S, et al. . Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med 2016; 8: 332ra46.
    1. Levin MJ, Schmader KE, Pang L, et al. . Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis 2016; 213:14–22.
    1. Leroux-Roels G, Marchant A, Levy J, et al. . Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol 2016; 169:16–27.
    1. Levin MJ, Kroehl ME, Johnson MJ, et al. . Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest 2018; 128:4429–40.
    1. Weinberg A, Kroehl ME, Johnson MJ, et al. . Comparative immune responses to licensed herpes zoster vaccines. J Infect Dis 2018; 218:81–7.
    1. Levin MJ, Weinberg A. Immune responses to zoster vaccines. Hum Vaccin Immunother 2019; 15:772–7.
    1. Cunningham AL, Levin MJ. Herpes zoster vaccines. J Infect Dis 2018; 218:127–33.
    1. Berry N, Manoussaka M, Ham C, et al. . Role of occult and post-acute phase replication in protective immunity induced with a novel live attenuated SIV vaccine. PLoS Pathog 2016; 12:e1006083.
    1. Maggioli MF, Palmer MV, Thacker TC, et al. . Increased TNF-α/IFN-γ/IL-2 and Decreased TNF-α/IFN-γ production by central memory T cells are associated with protective responses against bovine tuberculosis following BCG vaccination. Front Immunol 2016; 7:421.
    1. Mordmüller B, Surat G, Lagler H, et al. . Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 2017; 542:445–9.
    1. López-Fauqued M, Campora L, Delannois F, et al. . ZOE-50/70 Study Group . Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine 2019; 37:2482–93.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj